| Literature link | GPT Summary | Evidence category | Disease type |
|---|---|---|---|
| 38266822 | This study explored the association between fasting serum C-peptide concentrations in early pregnancy and the risk of gestational diabetes mellitus (GDM) in a nested case-control cohort of 436 Chinese women. Results showed that C-peptide levels significantly decreased from the first to the second trimester in women with normal glucose tolerance (NGT). However, higher C-peptide levels during the first and second trimesters were associated with a markedly increased risk of GDM, with odds ratios of 2.38 and 3.07, respectively. The predictive capacity of C-peptide was substantial, with areas under the ROC curves of 80.4% and 82.4% for the first and second trimesters. These findings suggest that fasting serum C-peptide is a strong predictor of GDM and could aid in early detection and intervention. | Risk factor | GDM |
| 35996181 | This study investigated the relationship between early-pregnancy serum C-peptide levels and the risk of gestational diabetes mellitus (GDM) in a nested case-control study involving 332 GDM cases and 664 matched controls. Results showed that women in the highest quartile of C-peptide had a 2.28-fold higher risk of GDM compared to those in the lowest quartile, even after adjusting for confounding factors (P for trend < 0.001). C-peptide was positively correlated with multiple metabolic biomarkers, including fasting insulin, HOMA-IR, fasting glucose, and triglycerides, and negatively correlated with HDL cholesterol and adiponectin. While adding C-peptide to a predictive model improved its performance slightly (C-statistic: 0.66 vs. 0.63; P = 0.008), further validation is required. These findings suggest that early-pregnancy C-peptide levels are positively associated with GDM risk and could have potential as a predictive biomarker. | Risk factor | GDM |
| KEGG pathway |
|---|
| Insulin secretion, Type II diabetes mellitus |
RF's name
C-peptide
RF's type
Insulin secretion function indicator